Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech’s Rituxan Fails Against PPMS

This article was originally published in The Pink Sheet Daily

Executive Summary

Late-stage lupus trial is still a wild card for anti-B-cell therapy.

You may also be interested in...



Biogen Idec Retains MS Focus, But It's "More Than Just Tysabri"

Biogen Idec made the case that it is a research-oriented biotech focused on home-grown therapeutic programs at the firm’s March 26 R&D day. It was an elaborately choreographed effort to remind investors that the firm is maintaining its focus on research and doesn’t plan to be a company that simply develops in-licensed products.

Biogen Idec Retains MS Focus, But It's "More Than Just Tysabri"

Biogen Idec made the case that it is a research-oriented biotech focused on home-grown therapeutic programs at the firm’s March 26 R&D day. It was an elaborately choreographed effort to remind investors that the firm is maintaining its focus on research and doesn’t plan to be a company that simply develops in-licensed products.

Side Effects Dampen Neurologists' Enthusiasm For Novel MS Drugs

With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development – from the first oral options to infrequently administered biologics – the treatment paradigm for the debilitating disease appears on the cusp of significant change.

Related Content

Topics

UsernamePublicRestriction

Register

PS067568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel